Moclobemid Stada (Moclobemide)

Moclobemide, the active ingredient in Moclobemid Stada, is a reversible MAO-A inhibitor presented as an oral tablet for oral use. It is prescribed for major depressive disorder and social anxiety disorder in adult patients. The drug works by increasing neurotransmitter levels in the brain, helping to improve mood and reduce anxiety symptoms.

GNH USA supplies Moclobemid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moclobemide is used to treat conditions within the depressive and anxiety disorder families by enhancing monoamine neurotransmission.

- Major depressive disorder: alleviates depressive symptoms such as low mood, loss of interest, and fatigue. - Social anxiety disorder: reduces fear of social situations and improves functional participation. - Anxiety symptoms associated with depression: may lessen accompanying anxiety and improve overall wellbeing.

Moclobemide may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and rare events.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: intermittent tension‑type headaches. - Insomnia: difficulty initiating or maintaining sleep. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Mild hypertension: slight increase in blood pressure.

Serious or Rare Side Effects: - Hypertensive crisis: sudden severe rise in blood pressure, especially with tyramine intake. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities. - Severe liver injury: jaundice, elevated liver enzymes. - Agranulocytosis: marked reduction in white blood cells. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychosis: emergence of hallucinations or delusional thoughts.

Before initiating therapy with Moclobemide, several safety considerations should be observed.

- Cardiovascular assessment: evaluate blood pressure and heart disease history. - Dietary restrictions: avoid tyramine‑rich foods to prevent hypertensive episodes. - Drug history review: screen for other MAO inhibitors or serotonergic agents. - Hepatic function: monitor liver enzymes in patients with liver disease. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Moclobemide can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Tyramine‑rich foods: risk of hypertensive crisis. - Other MAO inhibitors: additive inhibition of monoamine metabolism. - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonergic activity. - Tricyclic antidepressants (TCAs): heightened risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure lowering. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased bleeding risk. - Caffeine: may exacerbate nervous system stimulation. - Linezolid and other reversible MAO‑A antibiotics: monitor for serotonin syndrome. - Certain antipsychotics: watch for additive central nervous system effects.